Search Medical Condition
Please enter condition
Please choose location from dropdown

Endometrial Cancer Clinical Trials

A listing of Endometrial Cancer medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

RESULTS

Found (200) clinical trials

Longitudinal Evaluation of Women Undergoing Pelvic Exenteration for Treatment of Gynecologic Malignancy

Prospective Study Procedures: Study Procedures: If you agree to take part in this study, you will be asked to complete a series of questionnaires at specific times. The questionnaires ask questions about how you feel, what you are able to do, depression, coping, social support, sexual function, and your body ...

Phase N/A

A Study Evaluating MM-310 in Patients With Solid Tumors

MM-310 is a liposomal formulation of a docetaxel prodrug that targets the EphA2 receptor on cancer cells. Docetaxel is an approved chemotherapeutic drug.This study is a Phase 1 open-label study of MM-310 in patients with solid tumors. In the first part of the study, MM-310 will be assessed as a ...

Phase

SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

The SYNERGY Registry is an international prospective, observational cohort study of eligible adult and pediatric pts with advanced solid and hematological malignancies, for whom the decision to consider CTE has already been made by their primary providers (PP). Using a proprietary application programming interface (API) linked to existing electronic health ...

Phase N/A

Study of Mirvetuximab Soravtansine in Comb. With Bevacizumab Carboplatin PLD Pembrolizumab or Bevacizumab + Carboplatin in Adults With FRa + Adv. EOC Primary Peritoneal or Fallopian Tube Cancer

The dose escalation part of the study will assess safety and tolerability and determine the maximum tolerated dose (MTD) for each regimen. The dose expansion of the MTD will assess safety, tolerability and preliminary anti-tumor activity.

Phase

Hormone Receptor Positive endometrIal Carcinoma Treated by Dual mTORC1/mTORC2 Inhibitor and Anastrozole (VICTORIA)

TREATMENT PLAN : Following randomisation patients will receive Arm A : AZD2014 plus anastrozole or Arm B: anastrozole alone AZD2014 will be administered with an intermittent schedule i.e. 125 mg bis in die (BID) intermittent with 2 days on followed by 5 days off per week for a total weekly ...

Phase

Open-label Phase 1b Study of ARQ 092 in Combination With Carboplatin Plus Paclitaxel in Combination With Paclitaxel or in Combination With Anastrozole

This is an open-label Phase 1b, dose escalation study of oral ARQ 092 administered in combination with carboplatin plus paclitaxel (Carboplatin Plus Paclitaxel Arm) or in combination with paclitaxel alone (Paclitaxel Arm) in subjects with advanced, inoperable metastatic and/or recurrent solid tumors, or in combination with anastrozole (Anastrozole Arm) in ...

Phase

Serum Biomarkers in Diagnosis and Predicting Prognosis of Endometrial and Ovarian Cancers

This study evaluates the usefulness of serum levels of trefoil factor 3 (TFF3), secreted frizzled related protein 4 (sFRP-4), reactive oxygen species modulator 1 (Romo1) and nuclear factor (NF)-B as potential diagnostic and prognostic biomarkers in endometrial and ovarian carcinoma.

Phase N/A

Genetic Risk: Whether When and How to Tell Adolescents

The investigators currently lack an adequate understanding of how parents and children feel about genetic risk/status, how it is communicated, and how it influences wellbeing and family relationships. This understanding is vital in order for genetic counselors and other health care professionals to provide the best guidance possible to families. ...

Phase N/A

A Study of Coti-2 for the Treatment of Advanced or Recurrent Gynecologic Malignancies

This is a single arm, single center, open-label, Phase 1, first time in human study of COTI-2 in patients with recurrent ovarian,fallopian tube,primary peritoneal cancer, endometrial, cervical or head and neck cancer. COTI-2 will be self-administered as a single agent, orally, once daily for 5 days followed by 2 treatment-free ...

Phase

Radiation Therapy With or Without Cisplatin in Treating Patients With Recurrent Endometrial Cancer

PRIMARY OBJECTIVES: I. To assess whether pelvic radiation therapy with concurrent cisplatin is more promising with respect to progression-free survival than pelvic radiation therapy alone in the treatment of recurrent uterine carcinoma limited to the pelvis and vagina. SECONDARY OBJECTIVES: I. To capture the sites of recurrence subsequent to treatment ...

Phase